{"id":385614,"date":"2025-11-17T16:49:14","date_gmt":"2025-11-17T16:49:14","guid":{"rendered":"https:\/\/www.europesays.com\/us\/385614\/"},"modified":"2025-11-17T16:49:14","modified_gmt":"2025-11-17T16:49:14","slug":"ozempic-prices-lowered-after-trump-deal","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/385614\/","title":{"rendered":"Ozempic Prices Lowered After Trump Deal"},"content":{"rendered":"

Topline<\/p>\n

Novo Nordisk on Monday lowered the direct-to-consumer prices of its weight loss drug Wegovy and diabetes treatment Ozempic in a challenge to Eli Lilly\u2019s Zepbound after President Donald Trump announced a deal with the pharmaceutical firms to reduce the U.S. price tag of the popular drugs. <\/p>\n

Trump announced popular weight loss treatments would be offered directly on a new \u201cTrumpRx.gov\u201d website at lower prices.<\/p>\n

Copyright 2023 The Associated Press. All rights reserved.Key Facts<\/p>\n

The out-of-pocket monthly price of Ozempic and Wegovy is now $349 from $499 , with an offer for new cash-paying patients to purchase the two lowest doses of either drug for $199 per month for the first two months, Novo Nordisk announced<\/a>.<\/p>\n

Trump, who pushed for lower pharmaceutical costs in the U.S., announced<\/a> earlier this month a deal with Novo Nordisk and Eli Lilly for patients on Medicare and Medicaid to purchase the weight-loss drugs at a lower price on a new \u201cTrumpRx\u201d website.<\/p>\n

Dave Moore, Novo Nordisk\u2019s executive vice president of U.S. operations, said in a statement the company wants to make sure its drugs are \u201caffordable and accessible to those who need them.\u201d<\/p>\n

Lower costs for Ozempic and Wegovy align with Eli Lilly\u2019s price tag for Zepbound, which is offered a $349 per month for its lowest dosage. <\/p>\n

Novo Nordisk noted the cash-pay cost for the highest dose of Ozempic, a 2-milligram injection, would remain at $499 per month.<\/p>\n

The announcement made no impact on Novo Nordisk\u2019s shares, while Eli Lilly\u2019s stock declined slightly (0.2%).<\/p>\n

How Much Will Ozempic And Zepbound Cost Under Trump?<\/p>\n

Novo Nordisk and Eli Lilly will lower<\/a> the price Medicare pays for their GLP-1 treatments, which cost up to $1,350 per month before insurance, to $245 per month. Patients using the new TrumpRx.gov to purchase the drugs without insurance will pay $350 per month, with plans to lower costs to $250 per month over the next two years. A $149 per month charge for the lowest dose of the pill form of the drugs will be offered to consumers, Medicare and Medicaid when the drugs reach the market. Patients with severe obesity will have access to the treatments through Medicare with a $50 co-pay starting as soon as mid-2026, the companies said. <\/p>\n

Read More<\/p>\n","protected":false},"excerpt":{"rendered":"Topline Novo Nordisk on Monday lowered the direct-to-consumer prices of its weight loss drug Wegovy and diabetes treatment…\n","protected":false},"author":3,"featured_media":385615,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[69,25996,210,1060,9412,427,184224,184225,67,132,68,2402,184227,184226,15208],"class_list":{"0":"post-385614","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-donald-trump","9":"tag-eli-lilly","10":"tag-health","11":"tag-medication","12":"tag-novo-nordisk","13":"tag-ozempic","14":"tag-ozempic-price","15":"tag-ozempic-sot","16":"tag-united-states","17":"tag-unitedstates","18":"tag-us","19":"tag-wegovy","20":"tag-wegovy-cost","21":"tag-wegovy-price","22":"tag-zepbound"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115566068748054369","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/385614","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=385614"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/385614\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/385615"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=385614"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=385614"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=385614"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}